pathology assessments to establish cTNM and ypTNM stages has never been validated and may not be appropriate. Therefore, new cTNM and ypTNM stage groupings and prognostic information were added to the eighth edition to overcome these issues. New clinical
Search Results
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
about the reliability of biomarker testing in breast cancer. ASCO, the College of American Pathology, and NCCN issued technology assessments on methods to assure high-quality performance and interpretation of ER, PR, and HER2 testing. 3 - 6
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes
suspected uterine neoplasms, the initial evaluation/workup includes a history and physical examination, endometrial biopsy, and other studies (see UN-1, page 250). 7 An expert pathology review will determine whether a patient has either 1) a malignant
George Handzo, Jill M. Bowden, and Stephen King
publication of the third edition of the NCP guidelines. The panel chose “distress” as the focus of the 1997 NCCN Guidelines because that term did not represent or infer any kind of pathology. Efforts were made to describe distress as a normally expected
M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz
her tumor 3 weeks after discontinuing imatinib. Because of the location of the tumor and involvement of the SMV, a Whipple procedure was required. However, it was believed that the neoadjuvant imatinib made this procedure possible. Pathology revealed a
Katy K. Tsai, Neharika Khurana, Timothy McCalmont, Adil Daud, Boris Bastian, and Iwei Yeh
resected in late April 2015, with pathology indicating poorly differentiated clear cell carcinoma ( Figure 1 ). The tumor was 9.8 cm in greatest diameter and was excised with a positive margin. Focal perineural invasion and vaguely squamoid areas were also
Rajinder S. Grover, Kemp Kernstine, and Amrita Krishnan
final pathology. Figure 1 CT of the face, neck, and torso, and PET/CT showing FDG uptake. CT of the chest with contrast (A) reveals a large mass surrounding the distal esophagus measuring 6.0 x 3.7 cm and extending to the gastroesophageal
Brian J. Williams, Daniel M.S. Raper, Erin Godbout, T. David Bourne, Daniel M. Prevedello, Amin B. Kassam, and Deric M. Park
against chordoma. 46 Finally, brachyury, a histologic marker for chordoma, may also drive chordoma pathology. Transient genetic knockdown of brachyury in chordoma cells was found to induce differentiation and senescence. 47 Furthermore, brachyury has
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed
Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh
. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet 1997 ; 6 : 1383 – 1387 . 3 Starink TM Hausman R . The cutaneous pathology of extrafacial lesions in Cowden's disease . J Cutan Pathol 1984 ; 11 : 338
